Thrombolytic medications pose a risk of serious bleeding, and in some situations thrombolysis may therefore be unsuitable.[1] Thrombolysis can also play an important part inreperfusion therapy in blockedarteries.
Stroke: Thrombolysis reduces major disability or death when given within 3 hours (or perhaps even 6 hours) of ischaemic stroke onset when there are no contraindications to treatment.[3][4][5]
Massivepulmonary embolism. For the treatment of a massivepulmonary embolism,catheter-directed therapy is a safer and more effective alternative to systemic thrombolysis. This involves the injecting of drugs directly into the clot.[6]
Thrombolysis is usuallyintravenous. It may also be used directly into the affected blood vessel during anangiogram (intra-arterial thrombolysis), e.g. when patients present with stroke beyond three hours or in severe deep vein thrombosis (catheter-directed thrombolysis).[10]
Thrombolysis is not without risks. Therefore, clinicians must select patients who are to be best suited for the procedure, and those who have the least risk of having a fatal complication. An absolute contraindication is in itself enough to avoid thrombolysis, while a relative contraindication needs to be considered in relation to the overall clinical situation.[citation needed]
Uncertainty about time of stroke onset (e.g. patients awakening from sleep).
Coma or severe obtundation with fixed eye deviation and complete hemiplegia.
Hypertension: systolic blood pressure ≥ 185mmHg; or diastolic blood pressure >110mmHg on repeated measures prior to study (if reversed, patient can be treated).
Clinical presentation suggestive of subarachnoid haemorrhage even if the CT scan is normal.
Presumed septic embolus.
Patient having received a heparin medication within the last 48 hours and has an elevatedActivated Prothrombin Time (APTT) or has a known hereditary or acquired haemorrhagic diathesis
INR >1.7
Known advanced liver disease, advanced right heart failure, or anticoagulation, and INR > 1.5 (no need to wait for INR result in the absence of the former three conditions).
Severe neurological impairment with NIHSS score >22.
Age >80 years.
CT evidence of extensive middle cerebral artery (MCA) territory infarction (sulcal effacement or blurring of grey-white junction in greater than 1/3 of MCA territory).
Stroke or serious head trauma within the past three months where the risks of bleeding are considered to outweigh the benefits of therapy.
Major surgery within the last 14 days (consider intra-arterial thrombolysis).
Patient has a known history of intracranial haemorrhage, subarachnoid haemorrhage, known intracranial arteriovenous malformation or previously known intracranial neoplasm
Recent (within 30 days) biopsy of a parenchymal organ or surgery that, in the opinion of the responsible clinician, would increase the risk of unmanageable (e.g. uncontrolled by local pressure) bleeding.
Recent (within 30 days) trauma with internal injuries or ulcerative wounds.
Gastrointestinal or urinary tract haemorrhage within the last 30 days or any active or recent haemorrhage that, in the opinion of the responsible clinician, would increase the risk of unmanageable (e.g. by local pressure) bleeding.
Arterial puncture at non-compressible site within the last 7 days.
Concomitant serious, advanced or terminal illness or any other condition that, in the opinion of the responsible clinician would pose an unacceptable risk.
Minor or Rapidly improving deficit.
Seizure: If the presenting neurological deficit is deemed due to a seizure.
Pregnancy is not an absolute contraindication. Consider intra-arterial thrombolysis.
Hemorrhagic stroke is a rare but serious complication of thrombolytic therapy. If a patient has had thrombolysis before, an allergy against the thrombolytic drug may have developed (especially afterstreptokinase). If the symptoms are mild, the infusion is stopped and the patient is commenced on anantihistamine before infusion is recommenced.Anaphylaxis generally requires immediate cessation of thrombolysis.[citation needed]
Thrombolysis therapy uses thrombolytic drugs that dissolve blood clots. Most of these drugs target fibrin (one of the main constituent of blood clots) and are therefore called fibrinolytics. All currently approved thrombolytic drugs arebiologics, either derived fromStreptococcus species, or, more recently, usingrecombinantbiotechnology whereby tPA is manufactured using cell culture, resulting in a recombinant tissue plasminogen activator or rtPA.[citation needed]
A 2023meta-analysis of 44 studies[18] compared treatments forpulmonary embolism including thrombolytic therapy delivered through a catheter. Catheter-directed thrombolysis (CDT) methods included fragmentation and ultrasound use. CDT was associated with better outcomes than anticoagulation alone or systemic thrombolysis, but the studies were mostly small and observational.
In people who receive CDT, there is a risk of hemorrhage as a side effect. Scientists have studied whether measuringfibrinogen in blood can be used as abiomarker to predict hemorrhage. As of 2017 it was not known if this works or not.[19]
Researchers showed a 10-fold variation in the proportion of patients who received thrombolysis after stroke in England and Wales, ranging from 1 in 50 (2%) to 1 in 4 (24%). The team also showed that most of the variation was explained by hospital processes (such as how quickly people can have a brain scan) and in doctors' decision-making (who they think should or should not receive thrombolysis) rather than knowledge of the time of stroke.[20][21]
Prospective, randomized clinical trials to evaluate the utility of catheter-directed thrombolysis inpulmonary embolism include HI-PEITHO (Higher-Risk Pulmonary Embolism Thrombolysis).[22]
^Burchum, Jacqueline Rosenjack; Rosenthal, Laura D.; Lehne, Richard A. (2019).Lehne's pharmacology for nursing care (10th ed.). St. Louis, Missouri: Elsevier.ISBN978-0-323-51227-5.
^"Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group".Lancet.343 (8893):311–22. 5 February 1994.doi:10.1016/s0140-6736(94)91161-4.PMID7905143.
^Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV (November 2009). "Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques".J Vasc Interv Radiol.20 (11):1431–40.doi:10.1016/j.jvir.2009.08.002.PMID19875060.
^Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, Tan C, Chunilal SD, Ward CM, Baker R, Nandurkar H (March 2019). "New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism".The Medical Journal of Australia.210 (5):227–235.doi:10.5694/mja2.50004.hdl:11343/285435.PMID30739331.S2CID73433650.
^Thurman, Jason; Jauch, Edward C. (2002). "Acute ischemic stroke: emergent evaluation and management".Emergency Medicine Clinics of North America.20 (3):609–630.doi:10.1016/s0733-8627(02)00014-7.PMID12379964.
^Klok FA, Piazza G, Sharp AS, Ní Ainle F, Jaff MR, Chauhan N, Patel B, Barco S, Goldhaber SZ, Kucher N, Lang IM, Schmidtmann I, Sterling KM, Becker D, Martin N, Rosenfield K, Konstantinides SV (September 2022). "Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study".Am Heart J.251:43–53.doi:10.1016/j.ahj.2022.05.011.hdl:1887/3494555.PMID35588898.
